All In Biotech

Drug Trial Radar · NCT04508140

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

18

Actual

Start

Jun 17, 2020

Primary completion

Dec 2, 2022

Study completion Dec 2, 2022

Sponsor

Lead sponsor
Highlight TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open, single arm, multicenter phase 2 trial in which BO-112 will be administered intratumorally in combination with intravenous pembrolizumab in patients with liver metastasis from colorectal, gastric or gastroesophageal junction cancers. The objective is to reverse the primary resistance that a subgroup of patients from these tumors having microsatellite stability present to the PD-1 inhibitors. Treatment will be administered every 3 weeks, with the exception of the first cycle, in which BO-112 will be also administered on D8, for up to 2 years. The primary objective is overall response rate based on RECIST 1.1 and safety, specifically referred to treatment emergent adverse events (TEAEs) with severity ≥ Grade 3 related to the study treatment (NCI-CTCAE v 5.0). The secondary endpoints include other efficacy endpoints (duration of response, disease control rate, progression-free survival, overall survival at 6 months, all based on RECIST 1.1, and overall response rate based on a specific tumor assessment criteria to evaluate the response to immunotherapies, IRECIST) and safety, in this case considering the number and proportion of subjects with treatment TEAEs (any grade) . In addition, the changes in the tumor microenvironment induced by the injection of BO-112 will be also evaluated as exploratory endpoints.

Conditions

  • Colorectal Cancer
  • Gastric Cancer
  • Oesophageal Cancer

Interventions

  • Hepatic BiopsyProcedure

    In this trial a biopsy from the hepatic lesion to be injected will be mandatory on C1D1 and C2D1, prior to the BO-112 administration. On the same timepoints, a biopsy from a non-hepatic, non-injected lesion will be optional.

  • BO-112 with pembrolizumabDrug

    BO-112 was administered in the liver metastasis at the dose of 1mg (1.2 mL) in combination with intravenous pembrolizumab given at the fixed dose of 200 mg, every 3 weeks for up to 35 cycles (2 years). During the first cycle, BO-112 was administered on D1 and D8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-tumour Efficacy:Overall Response Rate (ORR) Based on RECIST 1.1Time frame: from baseline to approximately 8 months
  2. Safety: Adverse EventsTime frame: from baseline to approximately 8 months

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Institut Jules Bordet

    Brussels, Belgium

  • UCL St-Luc

    Brussels, Belgium

  • University Hospital Antwerp (UZA)

    Edegem, Belgium

  • Universitair Ziekenhus Gent

    Ghent, Belgium

  • IRCCS Ospedale Policlinico San Martino

    Genova, Italy

  • Azienda Ospedaliera Ospedale Niguarda Ca'Granda

    Milan, Italy

  • Hospital Valle Hebrón

    Barcelona, Spain

  • Hospital Gregorio Marañón

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Clínica Universitaria de Navarra

    Pamplona, Spain

  • Hospital Clínico de Valencia

    Valencia, Spain

  • Hospital Reina Sofía

    Córdoba, Cordoba, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.